Literature DB >> 29506615

Systematic case finding for tuberculosis in HIV-infected people who inject drugs: experience from Pakistan.

S Tahseen1, H Shahnawaz1, U Riaz2, F M Khanzada1, A Hussain1, W Aslam1, M von Euler-Chelpin3.   

Abstract

SETTING: Pakistan is a high tuberculosis (TB) burden country, moving from low human immunodeficiency virus (HIV) prevalence to a concentrated epidemic driven primarily by people who inject drugs (PWID). The Antiretroviral Treatment Adherence Unit (AAU) in Islamabad, Pakistan, is a residential facility that offers combined treatment for opioid dependence and HIV. OBJECTIVE AND
DESIGN: This retrospective study was conducted to assess TB prevalence among HIV-infected PWID referred to the AAU and to evaluate the diagnostic value of cough as a screening symptom. A single sputum sample was collected regardless of symptoms, and examined using smear, Xpert® MTB/RIF and culture.
RESULTS: Of 888 PWID, 71.5% submitted a sputum sample. More TB cases were detected using Xpert (n = 25) than with smear (n = 10) or culture (n = 20). A TB prevalence of 6141 per 100 000 was estimated based on seven cases already identified as being on anti-tuberculosis treatment and 32 newly diagnosed bacteriologically confirmed TB cases. Both cough and smoking (10 pack-years) were associated with increased TB prevalence. Only half of the TB cases reported cough. Rifampicin resistance was reported among 10% (3/29) of newly identified cases.
CONCLUSION: TB prevalence in HIV-infected PWID was 15 times higher than in the general adult population. As a screening symptom, cough has low diagnostic value.

Entities:  

Mesh:

Year:  2018        PMID: 29506615     DOI: 10.5588/ijtld.17.0390

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

Review 1.  Closing gaps in the tuberculosis care cascade: an action-oriented research agenda.

Authors:  Ramnath Subbaraman; Tulip Jhaveri; Ruvandhi R Nathavitharana
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-01-11

2.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

3.  GeneXpert Technology for the diagnosis of HIV-associated tuberculosis: Is scale-up worth it?

Authors:  Muhammad Saeed; Shahida Hussain; Saba Riaz; Farhan Rasheed; Maqsood Ahmad; Shagufta Iram; Mizna Arif; Tariq Hamid Rahmani; Ambereen Imran Anwar
Journal:  Open Life Sci       Date:  2020-06-30       Impact factor: 0.938

4.  A systematic review of the number needed to screen for active TB among people living with HIV.

Authors:  L H Chaisson; F Naufal; P Delgado-Barroso; H S Alvarez-Manzo; K O Robsky; C R Miller; J E Golub; A E Shapiro
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 3.427

5.  Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam.

Authors:  Nicolas Nagot; Vinh Vu Hai; Thuy Thi Thu Dong; Oanh Khuat Thi Hai; Delphine Rapoud; Giang Thi Hoang; Catherine Quillet; Khue Pham Minh; Roselyne Vallo; Thanh Tuyet Thi Nham; Joëlle Castellani; Jonathan Feelemyer; Don C Des Jarlais; Lan Phuong Nguyen; Hoi Van Le; Nhung Viet Nguyen; Luan Nguyen Quang Vo; Huong Thi Duong; Jean-Pierre Moles; Didier Laureillard
Journal:  Open Forum Infect Dis       Date:  2021-11-08       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.